CIRM Funds Development of New CAR T-Cell Therapy for Blood Cancers

Dr. Ezra Cohen, photo courtesy UCSD Patients with blood cancers often respond well to existing treatments. However, those therapies do not work for everyone. For patients whose disease resists standard treatment, options can be limited. To address that need, the California Institute for Regenerative Medicine (CIRM) has awarded $4.1 million to support the development of … Continue reading CIRM Funds Development of New CAR T-Cell Therapy for Blood Cancers

CIRM-funded trial for blood cancer releases promising new data

A CIRM-funded trial conducted by Oncternal Therapeutics in collaboration with UC San Diego released an interim clinical data update for patients with mantle cell lymphoma (MCL), a type of blood cancer. The treatment being developed involves an antibody called cirmtuzumab (named after yours truly) being used with a cancer fighting drug called ibrutinib. The antibody … Continue reading CIRM-funded trial for blood cancer releases promising new data

Encouraging Progress for Two CIRM Supported Clinical Trials

This past Wednesday was Stem Cell Awareness Day, a day that is meant to remind us all of the importance of stem cell research and the potential it has to treat a wide variety of diseases. On this day, we also released an independent Economic Impact Report that showed how $10.7 Billion (yes, you read … Continue reading Encouraging Progress for Two CIRM Supported Clinical Trials

CIRM-funded clinical trial shows encouraging results for patients with chronic lymphocytic leukemia & mantle cell lymphoma

Illustration courtesy of Oncternal Therapeutics I often joke that my job here at CIRM is to be the official translator for the stem cell agency. I have to translate complex science into everyday English that people without a science background – that includes me – can understand. Think I’m joking? Try making sense of this. … Continue reading CIRM-funded clinical trial shows encouraging results for patients with chronic lymphocytic leukemia & mantle cell lymphoma

A cancer therapy developed at a CIRM Alpha Stem Cell Clinic tests its legs against breast cancer

A Phase 1 clinical trial co-sponsored by CIRM and Oncternal Therapeutics, has started treating patients at UC San Diego (UCSD). The goal of the trial is to test the safety and anti-tumor activity of the Oncternal-developed drug, cirmtuzumab, in treating breast cancer. Breast cancer is the second most common cancer to occur in women, regardless … Continue reading A cancer therapy developed at a CIRM Alpha Stem Cell Clinic tests its legs against breast cancer